Artist's rendering of the pretomanid compound @TB Alliance

Tuberculosis (TB) is one of the deadliest infectious diseases in the world. More than ten million people worldwide contract it every year. The consequences are fatal for about 1.4 million people, which is more than any other infectious disease. Furthermore, the number of infections that have tuberculosis pathogens which cannot be treated with conventional antibiotics or alternative antibiotics are on the rise. Since 98 percent of TB infections affect people in developing and emerging countries, the market is hardly of interest to commercial businesses. There are few incentives for them to invest money in research and development. This means that by the start of the new millennium, almost no new tuberculosis drugs were developed.

Read all the articles in our archive by becoming a member of Innovation Origins. Sign up here as a supporter of independent journalism!

Become a member!

On Innovation Origins you can read the latest news about the world of innovation every day. We want to keep it that way, but we can't do it alone! Are you enjoying our articles and would you like to support independent journalism? Become a member and read our stories guaranteed ad-free.

About the author

Author profile picture Almut Otto is a writer and has over 30 years of know-how in the communications industry. She learned the trade of journalism from scratch in a daily newspaper and in a special interest magazine. After studying communication sciences in Munich, she worked as an international PR manager in the textile, shoe, outdoor and IT industries for a long time. For some years now, she has been concentrating more on her journalistic background. As a passionate outdoor and water sports enthusiast - her hobbies include windsurfing, kitesurfing, SUP boarding, sailing and snowboarding - she is particularly interested in keeping the oceans clean and shaping a sustainable future. In addition, she is always fascinated by the latest developments from the world's hardware and software laboratories.